News

Every 25 October, the MDS Alliance and its member groups around the world unite to raise awareness of Myelodysplastic Syndromes (MDS) – a rare type of blood cancer where the bone marrow does not produce enough healthy blood cells. MDS varies in severity. Some forms may remain mild and undetected for years, while others are…

United for MDS: Together for Better Patient Outcomes   This Blood Cancer Awareness Month, the MDS Alliance is driving the conversation around myelodysplastic syndromes (MDS), a rare group of blood cancers.   In 2024, we are focusing on how MDS patient organisations can be crucial in providing essential resources and support for patients and their…

We are thrilled to have the opportunity to attend the European Hematology Association (EHA) Congress in Madrid from June 13-16. The agenda will be packed with captivating activities aimed at advancing awareness and understanding of hematological conditions, like MDS. Additionally, attendees will delve into the latest research unveiled at EHA. These are some of the…

In 2022, the classification of myelodysplastic syndromes/neoplasms (MDS) took a significant step forward with the introduction of two new systems: the International Consensus Classification (ICC) and the 2022 World Health Organization (WHO-2022) classification. These frameworks, though similar in some aspects, diverge notably in terminologies and the definition of new entities. A recent research, published in…

More than 300 million people worldwide are living with a rare disease. Rare Disease Day is a global campaign that aims to raise awareness and offer support for those on a rare medical journey, including rare cancers such as MDS. This event takes place annually on the last day of February, which this year falls…

Patients with higher-risk myelodysplastic syndromes (MDS) face considerable challenges in disease management and often require caregiver support. Reports on the burden of caring for patients with advanced cancer suggest that caregivers receive insufficient support. Our research aimed to identify key challenges for caregivers of patients with higher-risk MDS. Key Summary Points Why carry out this…

October 25  Every year on October 25, the MDS Alliance and its member groups around the world come together to raise awareness of Myelodysplastic Syndromes (MDS) – a type of rare blood cancer where the bone marrow does not produce enough healthy blood cells. There are various types of MDS, some of which stay mild…

Impressions sur le 15 e symposium international MDS à Copenhague en mai 2019 – du point de vue des patients.

[ngg src=”galleries” ids=”52″ exclusions=”886,894,895,890,889,888,887,885,891,892″ display=”pro_mosaic” row_height=”180″] 🩸 Wenn Sie wegen MDS behandelt werden, sollten Sie sich frei fühlen, jede noch so unbedeutend erscheinende Frage zu stellen. Die Amerikanische Krebsgesellschaft hat eine Liste von Fragen zusammengestellt, die Sie Ihrem Arzt stellen können. Sie finden sie hier: “Questions to ask your doctor” #ThinkMDS #OrderaBloodCount #ThisIsBloodCancer Want to…

Dieses Video kann in Ihrem Browser nicht abgespielt werden. Eine Download-Version finden Sie unter Link-Addresse. Ausführliche Informationen finden Sie unter diesem Link. Was ist MDS? Myelodysplastische Syndrome (MDS) sind eine Gruppe von Blutkrankheiten, die das Knochenmark betreffen, d. h. den weichen inneren Teil der Knochen, der Blutzellen produziert. Bei MDS produziert das Knochenmark abnormale oder…